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Background: The need for new platinum antitumor drugs is underscored by the 
usefulness of cisplatin and carboplatin in chemotherapy and the resistance of 
many tumors to these compounds. Combinatorial chemistry could aid in the 
search for cisplatin analogs if fast, high-throughput assays were available. Our 
goal was to develop rapid cell-based assays suitable for high-throughput 
screening that accurately predict the cytotoxicity of platinum complexes. We 
examined the effects of platinum complexes and other agents on reporter-gene 
expression in cancer cells. 
Results: HeLa Tet-On cells with inducible enhanced green fluorescent protein 
(EGFP) were prepared. Cisplatin and other cis-disubstituted platinum 
complexes inhibited EGFP expression, with a strong positive correlation 
between EGFP inhibition and cytotoxicity. By contrast, frans-[Pt(NH,),CI,], 
other frans-platinum complexes, methyl methanesulfonate or heat shock 
stimulated EGFP expression. Northern and nuclear run-on analyses revealed 
that the changes in EGFP expression were at the level of transcription. In 
another reporter-gene assay in Jurkat cells, cisplatin, but not trans-[Pt(NH,),CI,] 
or K,[RCI,l, inhibited P-lactamase expression, as measured by hydrolysis of the 
fluorescent substrate CCFP. 
Conclusions: The EGFP results indicate that cytotoxic stress enhances 
transcription from the inducible promoter, whereas compounds able to form the 
1,2-intrastrand platinum-DNA cross-links repress transcription. Both 
fluorescence-based reporter-gene assays afford promising new approaches to 
platinum anticancer drug discovery. 
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Introduction 
The success of cis-[Pt(NH,)&l,] (cis-DDP or cisplatin) 
and carboplatin as chemotherapeutic agents, combined 
with the resistance of many tumors to these compounds, 
underscores the need for new platinum drugs [l]. 
Although combinatorial chemistry is a key component of 
many drug discovery efforts, there is only one report of its 
application to the search for cisplatin analogs [Z]. In order 
to facilitate the screening of combinatorial libraries of plat- 
inum complexes, fast, high-throughput assays are needed. 
Methods utilizing cultured cancer cells are desirable 
because they provide essential information about the 
uptake and metabolism of new compounds. The com- 
monly used cytotoxicity assays, however, are not ideal. 
The clonogenic or colony-counting method can take over 
one week to yield results, and the assay is not suitable for 
high-throughput screening [3]. Assays employing dyes 
such as neutral red [4], MTT [5] or sulforhodamine B [6] 
can be performed with the aid of robotics for high 
throughput, but the cells must be incubated for several 
days before quantitation. The goal of this research, there- 
fore, was to develop rapid cell-based assays suitable for 
high-throughput screening that accurately predict the 
cytotoxicity of platinum complexes. 
Transcription, a key step in gene expression, seemed at 
the outset to be a suitable focal point for assay develop- 
ment. The in vitro inhibition of replication and transcrip- 
tion by platinum-DNA adducts is well documented 
[7-91. Platinum complexes can also inhibit gene expres- 
sion in mammalian cells. In one study [lo], plasmids con- 
taining the B-galactosidase reporter gene under the 
control of the human cytomegalovirus (CMV) or simian 
virus 40 (SV40) early region (SVER) promoter, were 
modified with cis- or trans-DDP and transfected into 
mammalian cell lines. Cisplatin inhibited B-galactosidase 
transcription 2-3-fold better than the clinically ineffec- 
tive trans-DDP at equal adduct levels, a result attributed 
to more efficient bypass of trans-DDP adducts by RNA 
polymerase. In a series of transient transfections of CV-1 
monkey cells, cis- and trans-DDP both inhibited reporter- 
gene expression from various promoters [ll]. Cisplatin, 
unlike trans-DDP, inhibited expression from strong pro- 
moters better than from weak promoters, suggesting that 
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the targeting of highly expressed genes could contribute 
to the cytotoxicity of the cis isomer. In mouse tumor cells 
cisplatin, but not an equitoxic dose of trans-DDP, 
blocked transcription from the mouse mammary tumor 
virus (MMTV) promoter [12]. It was suggested that an 
alteration in DNA structure upon the formation of cis- 
platin adducts prevents chromatin remodeling and tran- 
scription-factor binding, both essential for transcriptional 
activation, an explanation consistent with the results of 
recent X-ray and nuclear magnetic resonance (NMR) 
studies [13-1.51. 
Cisplatin and other DNA-damaging agents can also stimu- 
late gene expression from promoters implicated in the 
cytotoxicity or resistance pathways. In mammalian cells, 
DNA damage can induce p53-dependent apoptosis or a 
SOS DNA repair type response that results in cell-cycle 
arrest, DNA repair and enhanced survival [16,17]. In 
mouse erythroleukemia cells, c-myc-driven chlorampheni- 
co1 acetyltransferase (CAT) expression was enhanced by 
cisplatin [18]. Activation of c-myc has been implicated in 
cisplatin resistance [19]. In melanoma cells, cisplatin and 
UV light both induce c-+n promoter activity, which is cor- 
related with apoptosis in many cell lines [ZO]. The effect 
of cisplatin on genes involved in the regulation of cell 
growth is reviewed in [Zl]. 
DNA damage also induces gene expression from promot- 
ers with no obvious role in cytotoxicity or resistance. Tran- 
sient and stable transfections of appropriate vectors in 
HeLa cells revealed that cisplatin inhibited CAT expres- 
sion from the SVER promoter and the adenovirus 2 major 
late promoter (MLP), but induced expression from the 
HIV-l long terminal repeat (LTR) and adenovirus 5 E3 
promoters [ZZ]. LTR induction was also observed in cis- 
platin-treated human and rat fibroblasts [23] and in HeLa 
cells treated with mitomycin C or UV light [24]. 
The promoter-specific effects of cis- and trans-DDP in 
mammalian cells imply that a reporter-gene assay could be 
a fast, convenient way to screen novel platinum complexes 
for biological activity. There have been only a few reports 
linking reporter-gene expression with cytotoxicity [2.5-271, 
and none of these directly correlates transcriptional effects 
with mammalian cell death. Until recently, reporter-gene 
assays were not convenient for high-throughput screening. 
A better alternative is the recently cloned Aequoria aictoria 
green fluorescent protein (GFP) [28-301. GFP has a 
stable, species-independent post-translational fluorophore 
that requires no cofactors or substrates and can be visual- 
ized in intact cells and tissues with readily available fluo- 
rescein isothiocyanate (FITC) excitation and emission 
filters. To improve upon existing fluorescence-based 
reporter-gene technologies, a method using B-lactamase 
as a reporter enzyme was recently developed [31]. The 
fluorogenic substrate CCFZ/AM is readily taken up into 
the cytoplasm of a cell, where esterases convert it to the 
membrane-impermeable substrate CCFZ. Upon excita- 
tion with violet light, intact CCFZ emits green fluores- 
cence, whereas the product of B-lactamase-catalyzed 
CCFZ hydrolysis emits blue light. It is therefore possible 
to distinguish expressing from nonexpressing cells by the 
colour of their fluorescence. The ratio of blue to green 
fluorescence intensities is a measure of B-lactamase 
expression, and the enzymatic amplification of the signal 
allows very low levels of expression to be detected. 
Because of the long (20-30 h) half-life of GFP in mam- 
malian cells [32], we examined the effect of platinum 
complexes on inducible GFP expression. A Tet-On 
system was chosen [33] where the gene of interest, 
enhanced GFP (EGFP), was cloned into a plasmid down- 
stream of the minimal early promoter of the CMV 
(PminCMV ). In the presence of doxycycline, the tet-respon- 
sive transcriptional activator (rtTA) binds and activates 
the tetracycline-responsive element (TRE), which in 
turn activates the CMV promoter. In this manner, the 
addition of doxycycline to the growth medium induces 
EGFP expression. Inducible B-lactamase expression in 
Jurkat cells was achieved by using a previously reported 
cell line [31] with the B-lactamase reporter under the 
control of a tandem trimer of nuclear factor of activated 
T-cells (NF-AT) binding sites and the G-protein- 
coupled muscarinic receptor under the control of the 
CMV promoter (CMV-MI-GPCR/NFAT-bla Jurkat or C2 
Jurkat). Treatment of the cells with the muscarinic 
agonist carbachol induced B-lactamase expression. A 
Jurkat cell line (CMV-bla) with constitutive B-lactamase 
expression was also used. 
We demonstrate in this paper that the cytotoxicity of 
platinum complexes can be predicted from their effect 
on either EGFP or B-lactamase expression in human 
cancer cells. The implications of the effect of different 
types of damaging agents on inducible EGFP expression 
are also discussed. 
Results 
Inducible EGFP expression in HeLa let-On cells 
To generate human cancer cells with inducible EGFP 
expression, HeLa Tet-On cells were stably transfected 
with pTRE-EGFP, with the hygromycin resistance 
plasmid pTK-Hyg added for selection. Fluorescence 
microscopy and western blotting (data not shown) con- 
firmed that several clones including C27 expressed EGFP 
in the presence of doxycycline. The time course of doxy- 
cycline induction of EGFP fluorescence in HeLa C27 is 
plotted in Figure 1. A 13.5 h induction period provided 
sufficiently high fluorescence readings, which were inde- 
pendent of the doxycycline concentration over a range of 
2.2-216 pM (data not shown). 
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Time course of EGFP induction in HeLa C27 cells. Cells were treated 
with 21.6 FM doxycycline. Error bars represent zk 1 esd. 
Effect of platinum complexes on EGFP expression in HeLa 
C27 cells 
A dose-dependent decrease in EGFP expression was 
observed when HeLa C27 cells were treated simultane- 
ously with cisplatin and doxycycline and examined after 
13.5 h (Figure Za). trans-DDP affected EGFP expression 
in a manner distinct from cisplatin. At the lower trans- 
DDP concentrations used, there was a dose-dependent 
increase in EGFP, followed by a sharp decrease at very 
high concentrations (Figure Zb). This effect was not 
observed in cells treated with trans-DDP alone; doxycy- 
cline induction was essential. Similar results were obtained 
using another clone (data not shown), indicating that the 
results were not unique to CZ7 cells. 
Whereas cisplatin treatment resulted in a dose-dependent 
decrease in EGFP expression, at extremely low concentra- 
tions the drug also caused a modest increase (twofold) in 
EGFP expression (see inset, Figure 2a). These results were 
consistently reproducible although the error remained large. 
The effect of a 13.5 h co-treatment with doxycycline and 
two major types of platinum complexes was tested. 
&Platinum complexes having chloride ligands in cis posi- 
tions mimicked cisplatin by inhibiting EGFP expression 
in a dose-dependent manner (Figure 3a). Complexes 
having chloride ligands in trans positions induced EGFP 
expression at low doses and inhibited it at high doses in a 
manner similar to trans-DDP (Figure 3b). Treatment with 
the noncytotoxic compound [Pt(dien)Cl]Cl had no effect 
on EGFP expression (data not shown). 
[a) 
‘O0I 
80- 
60- 
Concentration of 
cisplatin (FM) 
20- 
00 
0 20 40 60 80 
Concentration of cisplatin (KM) 
:b) 
160 260 3bo 460 
Concentration of trans-DDP (FM) 
Chemistry & Biology 
Effect of (a) cisplatin and (b) Vans-DDP treatment on EGFP 
expression in HeLa C27 cells. All samples were induced with 21.6 PM 
doxycycline for 13.5 h. Error bars represent f 1 esd. 
DAPI (4’,6-diamidino-2-phenylindole) staining (data not 
shown) revealed that a 16.5 h treatment with 20 PM cis- 
platin induced apoptosis in 50% of the C27 cells, that is, 
AC,, = 20 PM. After a 20 h treatment, the AC,, for cis- 
platin was 16 PM. Although trypan blue staining showed 
that a 20 h treatment with 360 PM trans-DDP killed more 
than 90% of the cells, under no conditions did trrans-DDP 
induce apoptosis in more than 15% of the HeLa C27 cells. 
Effect of other cytotoxic treatments on EGFP expression in 
HeLa C27 
To assess the generality of the platinum compound results, 
HeLa C27 cells were treated with several nonplatinum 
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Effect of cis- and traans-platinum complexes on EGFP expression in 
HeLa C27 cells. (a) cis-[Pt(NH,)(NH,C,H,,)CI,l (red squares); 
cis-[Pt(C,H,NH,),CI,l (blue circles); [Pt(lysine)CI,l (green triangles). 
(b) t,t,t-[PtCI,(OH),(NH,)(C,H,, NH,)] (or JM335) (green triangles); 
trans-[Pt(CH,NH,),CI,l (red squares). Error bars represent + 1 esd. 
cytotoxic agents. Methyl methanesulfate (MMS), an alky- 
lating agent, behaved like trans-DDP, stimulating EGFP 
expression at low doses and inhibiting it at high doses 
(Figure 4). Similarly, a short (< 90 min) 45°C heat shock 
caused a time-dependent increase in EGFP expression, 
whereas a 120 min treatment caused a decrease 
(Figure 4). Calicheamicin, on the other hand, was similar 
to cisplatin in causing only a decrease in EGFP expres- 
sion (data not shown). 
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Effect of methyl methanesulfonate (MMS) or 45°C heat shock on 
EGFP expression in HeLa C27. Cells were treated with MMS in 
serum-free medium for 1.5 h, then washed and induced in complete 
medium. After the heat shock cells were induced at 37%. Error bars 
represent + 1 esd. 
Northern and run-on analysis of EGFP transcription in 
HeLa C27 cells 
To determine whether changes in EGFP expression occur 
at the transcriptional or post-transcriptional level, HeLa 
C27 cells were treated with cytotoxic agents and subjected 
to northern analysis. A separate control was prepared for 
MMS, with cells treated in serum-free media for 1.5 h and 
then given fresh complete media before induction. As 
Figure 5a reveals, EGFP transcription was greatly 
enhanced by trans-DDP, MMS and heat-shock treatment 
and blocked by treatment with cisplatin. In addition to 
specific inhibition of the EGFP, there was also an overall 
decrease in transcription in the cisplatin-treated cells. 
The nuclear run-on transcription assays show that changes 
in EGFP expression in HeLa C27 cells treated with cis- 
platin or trans-DDP are due to inhibition or enhancement 
of transcription, respectively (Figure 5b). Cells were treated 
with doxycycline for EGFP induction and co-treated with 
cisplatin (15 pM) or trans-DDP (120 PM). Nuclei isolated 
from these cells were used in the run-on assay. Labeled 
mRNA for EGFP in the dot blots corresponding to treat- 
ment with doxycycline alone confirms induction of EGFP. 
Co-treatment with trans-DDP (120 pM) resulted in a dra- 
matic increase in EGFP transcription. A similar treatment 
with cisplatin (15 pM) caused a general decrease in tran- 
scription, however. Significantly, twice as many nuclei 
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Figure 5 
(a) Northern blot of RNA prepared from HeLa 
C27 cells treated with various cytotoxic 
agents. RNA was quantitated by 
phosphorimager analysis, and all readings 
were normalized for loading by using 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) results. (b) Nuclear run-on 
transcription assay of HeLa C27 cells induced 
for EGFP production in the presence and 
absence of platinum compounds, cisplatin 
(15 PM) and Vans-DDP (120 FM). Isolated 
nuclei were subjected to in vitro run-on 
transcription and the labeled nascent mRNA 
transcripts hybridized to dot blots containing 
EGFP and the control genes, GAPDH and 7s 
RNA. dox, doxycycline. 
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(-log) were required in the run-on assay to achieve radiola- 
be1 incorporation levels similar to those for the untreated 
cells and for cells treated with trans-DDP. 
Screening of platinum complexes by repotter-gene assays 
The 13.5 h co-treatment EGFP protocol and the colony 
counting cytotoxicity assay were used to determine the 
ICSO and LC,, values, respectively, for a series of plat- 
inum complexes in HeLa C27 cells. The results, which 
show a strong positive correlation between EGFP inhibi- 
tion and cell death, are plotted in Figure 6. Compounds 
such as cisplatin and cis-[Pt(NH,)(NH,C,H,,)Cl,], both 
used in the clinic, score best and would clearly have been 
Figure 6 
selected as antitumor drug candidates using this reporter- 
gene assay. The platinum-amino-acid compounds, on the 
other hand, do not appear to be worth pursuing on the 
basis of these results. 
To study the activity of platinum complexes with another 
reporter-gene assay, Jurkat C2 cells were treated with 
&DDP, trans-DDP and K,PtCl,. The carbachol-depen- 
dent induction of P-lactamase was quantitated by measur- 
ing the ratio of intact to cleaved CCFZ substrate 
(Figure 7a). The IC,, value was 8 /.tM for cisplatin, but 
neither trans-DDP nor K,PtCl, blocked p-lactamase 
induction at concentrations up to 100 /.tM. Trypan blue 
Comparison of IC,, with LC,, for treatment of 
HeLa C27 cells with a series of platinum 
complexes. 
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as Effect of platinum-compound treatment on P-lactamase expression, 
measured by CCFP cleavage, in two Jurkat cell lines. (a) C2 Jurkat 
cells were treated with platinum for 20 h and then induced with 
carbachol for 4 h. (b) CMV-bla Jurkat cells were treated with platinum 
for 24 h. Error bars represent f 1 esd. 
and DAPI staining of Jurkat C2 cells revealed an LC,, 
value of 30 pM and an AC,, value of 15 PM for a 19.5 h 
cisplatin treatment. trans-DDP had an LC,, of 100 yM 
after 19.5 h, but never caused apoptosis in more than 35% 
of the cells. The CCFZ cleavage assay was repeated 
(Figure 7b) in the constitutively expressing CMV-bla 
Jurkat cell line. In that case, the IC,,, was 10 l.tM for cis- 
platin, 100 l.tM for trans-DDP and K,PtCl, did not affect 
B-lactamase expression. The images in Figure 8 compare 
CMV-bla Jurkat cells treated with cisplatin and trans- 
DDP to the dye-loaded, unplatinated control cells. 
Discussion 
Inducible expression of EGFP in HeLa Tet-On cells 
The effects of cytotoxic agents on EGFP expression in 
HeLa C27 cells discovered in the present study are 
unprecedented in that different agents yielded two distinct 
types of responses. For one class of cytotoxic agent, includ- 
ing trans-DDP, other trans-platinum complexes, and, to a 
greater extent, MMS and heat shock, EGFP expression 
rose sharply, reached a maximum, and then fell with 
increasingly toxic treatments. The second class included 
cisplatin, other &-platinum complexes, and calicheamicin, 
in which a dose-dependent decrease in EGFP expression 
occurred. Very low (< 2 PM) concentrations of cisplatin 
caused an -200% increase in EGFP expression relative to 
the untreated control, quite modest compared to the 
maximal values of 800%, 2100% and 2500% for trans-plat- 
inum complexes, MMS and heat shock, respectively. 
Northern analysis revealed a correlation between EGFP 
fluorescence and transcription of the gene; furthermore, 
cisplatin-treated cells had a lower total RNA content than 
others, indicating an overall decrease in transcription. Run- 
on analysis indicated that these changes occur at the level 
of transcription rather than mRNA stabilization. Although 
various forms of DNA damage can influence reporter-gene 
expression positively or negatively, there are no reports in 
which different genotoxic agents cause opposite effects on 
transcription from the same promoter. There are also no 
examples of a single cytotoxic agent both enhancing and 
inhibiting gene expression from the same promoter in a 
dose-dependent manner. 
The contrasting effects were not a function of overall cyto- 
toxicity. For example, trans-[Pt(NH,CH,),C&] caused a 
dose-dependent increase in EGFP expression from 1-5 
times its LC,, value of 8 yM. By contrast, [Pt(lysine)Cl,], 
brought about a dose-dependent decrease at values 
ranging from 0.3-5 times its 70 pM LC,, value. Apoptosis 
cannot explain the different effects either. Heat shock 
[34,35], MMS [36] and JM335 [37] all induce both apopto- 
sis and EGFP expression, whereas trans-DDP stimulates 
EGFP expression but kills cells using a nonapoptotic 
mechanism. The results are also unlikely to be a conse- 
quence of the specific site of integration of pTRE-EGFP 
into the host genome, because similar results were 
obtained with an independent HeLa clone. 
The upregulation of the EGFP by heat shock, as well as 
by several DNA-damaging agents, suggests that it is a 
general ‘response to stress. The mammalian stress 
response involves the induction of many types of gene 
products including heat-shock proteins [25,38], stress- 
activated protein kinases (JNK/SAPK) [39,40], the p53- 
dependent cell-cycle arrest and apoptosis pathway 
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proteins and DNA repair enzymes [16,17]. Although the 
Tet-On gene expression system is not endogenous to 
mammalian cells, this artificial construct, once activated 
by doxycycline, could nonetheless also be upregulated by 
stress. The damage induced by &-platinum complexes 
and calicheamicin must be different from other forms of 
stress. It is not surprising that calicheamicin blocks gene 
expression, for it is a highly toxic compound that rapidly 
enters cells, cleaves DNA and induces apoptosis in less 
than 4 hours [41,42]. The inhibition of EGFP transcrip- 
tion by many &platinum complexes, of variable toxicity 
but all capable of forming l,Z-intrastrand DNA cross- 
links, suggests a structural effect with mechanistic conse- 
quences. The bending and unwinding of DNA (reviewed 
in [43]) induced by the I,&intrastrand cross-link could 
lead to differential recognition by proteins such as SSRPl 
[44,45], which is involved in the elongation of transcrip- 
tion through nucleosomes (G. Orphansides, W-H. Lu, 
W.S. Lane, M. Hampsey and D. Reinberg, personal com- 
munication), or the TATA-binding protein [46], both of 
which recognize and bind to this platinum adduct but not 
to the tran.+DDP-DNA adducts. Such binding would 
account for the transcriptional consequences of cis-plat- 
inum adducts compared to most other types of damage. 
The modest increase in EGFP at low doses of cisplatin 
could result from the conflicting influences of stress 
response and the unique structural consequences of its 
DNA adducts. 
Cisplatin-DNA adducts are recognized by a variety of pro- 
teins [47], including those involved in nucleotide-excision 
repair (NER), DNA-mismatch repair, and the high mobil- 
ity group (HMG)-domain proteins. It seems unlikely that 
either of the repair systems is responsible for the different 
transcriptional effects, because NER processes recognize 
trans-DDP intrastrand cross-links [48] and the mismatch- 
repair pathway recognizes MMS damage [49]. The HMG- 
domain proteins, which specifically recognize DNA 
damaged by c&-platinum complexes but not trans-plat- 
inum complexes or any of the other agents tested, could 
be involved. HMG-domain proteins might contribute to 
cisplatin cytotoxicity by blocking or shielding 
cisplatin-DNA adducts from repair [43,50-521. Repair 
blockage would cause &-platinum cross-links to be more 
persistent than other forms of DNA damage. If upregula- 
tion of the EGFP is a response to stress in HeLa (2’27 cells, 
however, then persistent DNA adducts might be expected 
further to induce rather than to block EGFP expression, 
unless the shielding is so effective that this damage is 
completely unrecognized. 
It has also been proposed that cisplatin adducts could 
titrate HMG-domain proteins away from their natural 
binding sites [53]. Because many HMG-domain proteins 
serve as transcription factors, such an event could lead to 
cell death through the misregulation of transcription [54]. 
If the transcription factors necessary for EGFP induction 
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specifically recognize cisplatin-DNA adducts, then doxycy- 
cline- and stress/doxycycline-induced EGFP transcription 
would be prevented by cisplatin and its structural analogs. 
SSRPl is a candidate for this activity ([44,45]; G. Orphan- 
sides, W-H. Lu, W.S. Lane, M. Hampsey and D. Reinberg, 
personal communication). The titration mechanism would 
also explain the modest increase in EGFP expression at low 
levels of cisplatin. Only when a sufficient number of 
adducts formed would titration be effective. 
The titration hypothesis would also apply to non-HMG- 
domain transcription factors. The basal transcription 
factor TATA binding protein/TFIID (TBP) has been 
reported to recognize both cisplatin- and UV-damaged 
DNA [55]. In a subsequent study [46], DNA modified 
with a series of damaging agents was assayed for TBP 
binding and for transcription inhibition in HeLa whole- 
cell extracts. For each type of adduct tested, TBP binding 
correlated with transcription inhibition, with cisplatin and 
cis-[Pt(dach)Cl,] (dach, 1Jdiaminocyclohexane) having 
strong effects. In some experiments, trans-DDP-modified 
DNA bound TBP and inhibited transcription slightly, 
whereas MMS and [Pt(dien)Cl]Cl (dien, diethylenetri- 
amine) did neither. It was proposed that the kinked DNA 
structure formed by &-platinum adducts resembles the 
TBP-binding site and can thus titrate the protein away 
from its normal transcriptional activator region. These 
results are entirely consistent with the present EGFP 
expression results, and the observation that trans-DDP 
enhances EGFP expression to a lesser extent than MMS 
or heat shock could be explained by low-level transcrip- 
tion factor binding, as observed in the TBP study. 
The use of reporter-gene assays for screening platinum 
complexes 
The EGFP and B-lactamase reporter-gene assays are both 
good methods for screening platinum complexes to predict 
cytotoxicity. The EGFP induction assay yielded a good 
correlation between LC,, and IC,, values for a series of 
known platinum complexes. Use of a range of sample con- 
centrations in the EGFP assay reveals that gene expression 
is stimulated at low doses. Nevertheless, the IC,, value 
ultimately obtained correlated well with the LC,, results 
despite the initial increase. The EGFP method is much 
faster than any currently available cytotoxicity assay, but 
modest levels of EGFP induction at the 13.5 h time point 
require the cells to be lysed in a small volume of buffer and 
transferred to smaller wells in order to intensify the fluores- 
cence signal. The j3-lactamase CCFZ/AM assay is the 
better alternative for high-throughput screening. This 
method, which showed a dose-dependent decrease in gene 
expression upon treatment with cisplatin but not with inef- 
fective platinum complexes, also surpasses existing cyto- 
toxicity assays in speed. The results are available within 
24 h of platinum treatment, and the assay can be performed 
with the aid of robotics for convenient high-throughput 
screening. Inducible B-lactamase expression can be easily 
quantitated because of enzymatic amplification of the fluo- 
rescence signal. Because of the short (3.5 h) half-life of the 
enzyme, platinum-induced changes in constitutive B-lacta- 
mase expression can also be observed in less than 24 h. 
An additional advantage to both reporter-gene assays is 
that they screen platinum complexes for DNA damage 
that inhibits gene expression, rather than measuring cell 
death as an endpoint. In that sense, they are mechanism- 
based screening methods. Because the construction of 
stable cell lines expressing reporter genes can take several 
months, the choice of cell type for platinum drug screen- 
ing should be made judiciously. 
Significance 
The success of cisplatin and carboplatin as anticancer 
drugs, combined with the resistance of many tumors to 
platinum chemotherapy, have driven the search for new 
platinum antitumor drugs. With appropriate synthetic 
approaches and high-throughput screening methods, com- 
binatorial chemistry could accelerate the drug discovery 
process. We have demonstrated the utility of two fluores- 
cence-based methodologies for quickly screening platinum 
complexes in human cancer cells. These assays, which 
measure the inhibition of reporter-gene expression by 
cytotoxic platinum complexes, focus on biochemical 
processes rather than merely cytotoxic endpoints. Both 
methods, enhanced green fluorescent protein (EGFP) 
induction and hydrolysis of a cephalosporin substrate 
(CCF2), provide results in under 24 h, surpassing the 
speed of the commonly used cytotoxicity assays. Addition- 
ally, the EGFP induction assay is unique in that many 
forms of cytotoxic stress cause an upregulation of doxycy- 
cline-inducible EGFP transcription, whereas &platinum 
compounds inhibit EGFP transcription. This contrasting 
effect suggests that the bent and unwound structure of the 
1,2-intrastrand platinum-DNA cross-link modulates the 
cellular response to &platinum compounds, possibly 
because components of the transcriptional initiation or 
elongation machinery bind to the kinked complex. 
Materials and methods 
Materials 
Tissue culture media and antibiotics were purchased from Gibco BRL. 
Tet System Approved fetal bovine serum, pEGFP-1, pTRE, pTK-Hyg, 
HeLa Tet-On cells and anti-GFP antibody were obtained from Clontech. 
The plasmid containing 7s RNA was a gift from B. Panning and P.A. 
Sharp (MIT). Escherichia co/i containing the plasmid for GAPDH was 
obtained from the American Type Culture Collection (ATCC). Restriction 
enzymes and T4 DNA ligase were obtained from New England Biolabs. 
[c$*P] UTP was obtained from du Pont and ATP, GTP and CTP from 
Boehringer Mannheim. Cisplatin and JM335 were provided by Johnson- 
Matthey. All other platinum complexes were available in the laboratory, 
Calicheamicin was donated by P. Dedon (MIT). 
Physical measurements 
EGFP fluorescence measurements were recorded by using a Molecular 
Devices Fmax instrument equipped with a 465 + 14 nm excitation filter 
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and a 538 f 30 nm emission filter. CCFP fluorescence was measured 
by using a Cytofluor 4000 microtiter plate fluorimeter with a 
395 & 10 nm excitation filter and emission filters of 460 f 20 nm (blue 
fluorescence) and 530 f 15 nm (green fluorescence). In both cases the 
emission values were corrected by subtracting readings from blank 
wells. Images of cells plated onto poly-L-lysine coated glass cover slips 
were captured onto Kodak 400 ASA slide film with an inverted epifluo- 
rescence microscope (Zeiss) through a 63 x 1.25 numerical aperture 
(N.A.) oil immersion objective. Slides were scanned and the images digi- 
tized. Automated DNA sequencing was performed on an ABI Prism 
system at the MIT Biopolymers Laboratory. Platinum concentrations, rel- 
ative to a potassium hexachloroplatinate(IV) standard, were determined 
using a Varian model AA-1475 atomic absorption spectrophotometer, 
equipped with a GTA-95 graphite tube atomizer. Phosphorimager analy- 
ses were performed on a BioRad Molecular Imager. 
Cloning of p JRE-EGFP 
The EGFP gene was PCR-amplified from pEGFP-1. The 36nucleotide 
primer for the coding strand, 5’-TCTCGAGCTCAAGCTTCGAATTCT- 
GCAGTCGACGGT-3, included the 5’ and 3’ sequences adjacent to 
the EcoRl restriction site preceding the EGFP start codon in pEGFP-1. 
The 36nucleotide primer for the anticoding strand, 3’-ATITCGCCG- 
GCGCTGAGATCTAGTATTAGTCGG-TAT-5’, included the sequences 
adjacent to the Xbal site following the EGFP stop codon in pEGFP-1. 
PCR was performed in an EZStart 100 reaction tube (Molecular Bio- 
Products) with 0.2 ug template DNA, 0.5 ug each primer and 5 units 
F’fu polymerase (Stratagene) in a total volume of 50 pl. The products 
were precipitated with ethanol, digested with EcoRl and Xbal and pre- 
cipitated again. The pTRE vector was digested with EcoRl and Xbal, 
purified on a lo/, agarose gel and ligated to the EGFP insert using T4 
DNA ligase. The identity of the resulting plasmid pTRE-EGFP was veri- 
fied by restriction mapping and automated DNA sequencing. 
Jransfection of HeLa Jet-On cells with p JRE-EGFP 
HeLa Tet-On cells were cultured in D-MEM with 10% fetal bovine 
serum, 100 pglml of penicillin, 100 units/ml of streptomycin and 
400 Kg/ml of geneticin. The cells were transfected using the calcium 
phosphate method 1561 with Sspl-linearized pTRE-EGFP and to confer 
hygromycin resistance, Hi&Ill-linearized pTK-Hyg. The selective 
medium contained all of the growth medium components and 0.2 mg/ml 
of hygromycin. The resistant colonies were grown to confluence on 
35 mm plates, induced with 4.3 PM doxycycline and examined by fluo- 
rescence microscopy using an FITC filter pair. Extracts were prepared 
from five fluorescent clones and analyzed for inducible EGFP expression 
by Western blotting with a polyclonal anti-GFP antibody. The clone 
selected for high inducible expression with low background was C27. 
EGFP expression assay in HeLa C27 ceils 
HeLa C27 cells were maintained in selective media. 24 h before induc- 
tion, the cells were distributed in six-well plates such that they would be 
60-700/o confluent upon induction. Aqueous 0.4-2.0 mM platinum solu- 
tions were prepared no more than 2 h before use, and platinum concen- 
trations were confirmed by atomic absorption spectroscopy. In a typical 
co-treatment experiment, the platinum complexes were added to each 
well together with 21.6 uM doxycycline. After a 13.5 h incubation, the 
cells were washed with PBS and lysed by vigorous shaking in 125 pl of 
PBS with 0.5% SDS. The lysate samples were transferred to black 96- 
well microplates for fluorescence plate reading. A 4 ul aliquot of lysate 
was removed from each sample and used in the Nano-Orange protein 
assay (Molecular Probes). The EGFP fluorescence values were divided 
by their respective protein assay readings to correct for variations in cell 
plating. The corrected fluorescence values were then normalized relative 
to the control (unplatinated) samples. All samples were prepared in trip- 
licate, and the data were averaged with error bars representing one 
standard deviation. 
Northern blotting of RNA from HeLa C27 extracts 
For northern blotting analysis, HeLa C27 cells were distributed on 
10 cm plates and grown to 70% confluence. Parallel samples for the 
EGFP expression assay were prepared in triplicate on six-well plates. 
The cells were treated with the indicated cytotoxic agents and induced 
for 13.5 h with doxycycline. RNA was isolated from cell extracts by 
using the Biotecx Ultraspec-ll kit. After agarose-formaldehyde gel elec- 
trophoresis, the RNA was transferred to nitrocellulose and processed 
according to standard procedures [571. The blot was probed with 
random primer-labeled DNA encoding EGFP and, as a control, human 
GAPDH. The blot was quantitated by phosphorimager analysis, and 
EGFP values were corrected for loading by normalizing to the ubiqui- 
tously expressed GAPDH. 
Nuclear run-on transcription 
HeLa C27 cells were grown in monolayers on 15 cm plates (Falcon) to 
-60% confluence. EGFP induction was initiated by replacing the 
media and adding doxycycline (21.6 PM). The cells were co-treated 
with cisplatin (15 PM) or trams-DDP (120 PM) and harvested 12 h later 
by trypsinization. The nuclei were isolated as described [581 and either 
used immediately or stored in liquid nitrogen. 
The in viho run-on assay was performed by following a previously 
described protocol 1581. Briefly, run-on transcription was initiated by 
the addition of ATP, CTP and GTP and [a-szP] UTP (3000 CilmM)] to 
5-l 0 x 1 O7 in suspension and incubated for 30 min at 30°C with slow 
shaking. The reactions were stopped by treatment with RNase-free 
DNase, proteinase K and SDS as described previously [58]. The solu- 
tions were extracted with phenol/chloroform/isoamyl alcohol (pH 5.2) 
until the interface was clear. The separated aqueous layer was supple- 
mented with 100 ug carrier tRNA and precipitated by using trichlo- 
racetic acid. Acid insoluble material was filtered onto glass filters 
(Schleicher & Schuell) in a vacuum manifold and washed extensively. 
The filters were treated with RNase-free DNase and the labeled mRNA 
was extracted as described. After a proteinase K/SDS treatment, the 
solutions were extracted with phenol/chloroform/isoamyl alcohol and 
precipitated by using ethanol. Incorporated radiolabel varied between 
2.5 and 5 x 1 O6 cpm. The specific run-on transcripts were identified by 
hybridizing the labeled mRNA with dot blots containing genes of inter- 
est. Blots were prepared by immobilizing 10 ug of linearized and dena- 
tured plasmids with the genes for GFP, GAPDH and 7s RNA onto 
nitrocellulose filters with a dot-blot apparatus (Schleicher & Schuell). 
The filters were prehybridized for 12-l 6 h in a Hybaid oven at 55°C in 
a formamide buffer, 50% formamide, 5 x Denhardt’s solution, 5 x SSC, 
0.2% SDS, 100 uglml salmon sperm DNA. Equal counts of the labeled 
mRNA transcripts were added to the blots and incubated for -36 h at 
55°C. The blots were washed twice in 2 x SSC, each time for 1 h at 
55’C, treated with RNase A (10 ug/ml) for 15 min at 37”C, washed 
and phosphorimaged. 
Cytotoxicity and apoptosis assays 
For HeLa C27 cells, colony counting cytotoxicity assays were per- 
formed as previously described [21. All samples were prepared in 
triplicate, and platinum concentrations were verified by atomic 
absorption spectroscopy. For apoptosis assays, HeLa C27 cells 
were distributed on 24-well plates 24 h prior to platinum treatment. 
After treatment, the supernatant medium was transferred to micro- 
centrifuge tubes, and the cells were washed with PBS, which was 
transferred to the same tubes, The cells were trypsinized, added to 
the tubes, pelleted and DAPI-stained. 
Jurkat C2 cells were maintained at 1 O-50 x 1 O4 cells/ml in RPMI 1640 
medium supplemented with 10% fetal bovine serum, 100 f.rg/ml peni- 
cillin and 100 units/ml streptomycin. Prior to platinum treatment, the 
cells were diluted to 10 x 1 O4 cells/ml and distributed in 0.5 ml aliquots. 
Cell viability was measured by the trypan blue exclusion assay and 
apoptosis, by DAPI staining. All samples were prepared in duplicate. 
P-Lactamase expression assay in Jurkat cells 
Jurkat C2 cells in RPMI media were distributed into black 96-well clear- 
bottom microtiter plates at 100,000 cells per well. The platinum com- 
plexes were freshly dissolved at 1 mM concentration in water. Serial 
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dilutions of these solutions were prepared in water and added in 100/o of 
final volume to the cells. After a 20 h platinum treatment, the cells were 
induced with 100 uM carbachol for 4 h. Cells were then loaded with 
1 uM CCFPlAM at room temperature for 1 h, followed by plate reading 
for green and blue fluorescence. After background correction, the signal 
from the blue channel was divided by the signal from the green channel 
to obtain the final blue to green intensity ratio. With the gain settings 
used for this experiment, a population with > 95% of the cells express- 
ing 5-lactamase gave a ratio of greater than 3.0 and a population of with 
no cells expressing p-lactamase gave a ratio of 0.1-0.2. Jurkat cells 
constitutively expressing 5-lactamase under the control of the CMV early 
promoter (CMV-bla Jurkat) were treated in the same manner as the C2 
clone, but were kept 24 h in the incubator without any induction period 
prior to dye loading. All samples were prepared in quadruplicate, and 
the data were averaged with error bars representing standard error 
(standard deviation/square root of number of multiples). 
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